Article Text

Download PDFPDF
Prolonged Conservative Treatment of Endometrial Cancer Patients: More Than 1 Pregnancy Can Be Achieved
  1. Tamar Perri, MD*,,
  2. Jacob Korach, MD*,
  3. Walter H. Gotlieb, MD, PhD,
  4. Mario Beiner, MD*,
  5. Dror Meirow, MD,
  6. Eddie Friedman, MD§,
  7. Alex Ferenczy, MD and
  8. Gilad Ben-Baruch, MD*
  1. * Department of Gynecologic Oncology, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
  2. Division of Gynecologic Oncology, McGill-Jewish General Hospital, Montreal, Quebec, Canada; Departments of
  3. IVF and
  4. § Pathology, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; and
  5. Department of Pathology, McGill-Jewish General Hospital, Montreal, Quebec, Canada.
  1. Address correspondence and reprint requests to Tamar Perri, MD, Department of Gynecologic Oncology, Sheba Medical Center, 52621 Tel Hashomer, Israel. E-mail: tamarperri{at}


Background: Preserving reproductive function in young patients with early endometrial cancer is an accepted concept today. The safety and feasibility of long-term conservative treatment, allowing more than 1 pregnancy, remain to be ascertained.

Methods: This study was a retrospective chart review of a 27 women with endometrioid adenocarcinoma of the endometrium, who were treated conservatively at 2 tertiary-care institutions. Treatment comprised oral high-dose progestins with or without a levonorgestrel-releasing intrauterine device. Endometrial biopsy was repeated every 2 to 3 months.

Results: Over 7.8 to 412 months (median, 57.4 months), tumors regressed completely in 24 (89%) of 27 patients and partially in 2 patients, with 79% responding within 1 to 17 months. Of the complete responders, 15 (62%) of 24 had a recurrence; 4 underwent hysterectomy, and 11 underwent subsequent progestational treatment. All 11 responded, and 3 subsequently conceived. After 2 to 4 years, 5 patients again had a recurrence, of whom 3 underwent hysterectomy. Overall, 2 patients developed ovarian adenocarcinoma. All patients are currently disease-free. Conception occurred in 14 (51.8%) of 27 patients, in 5 more than once. There were 17 live births, and 2 patients are pregnant.

Conclusions: According to our data, prolonged progestational therapy for early-stage endometrial adenocarcinoma, allowing women to conceive, is feasible and apparently does not alter clinical outcome. Patients should be advised of the high recurrence rate and possible concomitant ovarian malignancy.

  • Endometrial carcinoma
  • Progestins
  • Conservative treatment
  • Fertility preservation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare that there are no conflict of interest and no financial support.